3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • ID: 3895074
  • Report
  • 41 pages
  • Global Markets Direct
1 of 6
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)
- The report reviews 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Overview

Therapeutics Development

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Products under Development by Stage of Development

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Products under Development by Therapy Area

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Products under Development by Indication

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Products Glance

Early Stage Products

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Products under Development by Companies

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Arno Therapeutics, Inc.

Sunesis Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Drug Profiles

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCI-1680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCI-1708 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHT-427 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNS-229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Dormant Projects

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Featured News & Press Releases

Nov 09, 2015: Sunesis Pharmaceuticals Presents Preclinical Data From Its PDK1 Inhibitor SNS-229 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis

Oct 27, 2015: Sunesis Pharmaceuticals Announces Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12

Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases

Aug 27, 2009: Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway

May 11, 2009: FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Arno Therapeutics, Inc., H2 2016

Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016

Pipeline by Tolero Pharmaceuticals, Inc., H2 2016

Dormant Projects, H2 2016 29List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) 3-phosphoinositide dependent protein kinase-1 (PDPK1) is a protein encoded by the PDPK1 gene. It plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It activates PPARG transcriptional activity and promotes adipocyte differentiation. It controls proliferation, survival, and growth of developing pancreatic cells. It essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis.

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by Companies in Phase I and Preclinical stages are 1 and 4 respectively.

Our latest report 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) – Pipeline Review, H2 2016, outlays comprehensive information on the 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Arno Therapeutics, Inc.
Sunesis Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll